两种硝基咪唑类抗结核新药对耐多药结核分枝杆菌的药物敏感性分析OA北大核心CSTPCD
Drug susceptibility analysis of the nitroimidazoles delamanid and pretomanid against multidrug-resistant Mycobacterium tuberculosis
目的 对德拉马尼(delamanid,DLM)和普瑞玛尼(pretomanid,PMD)两种硝基咪唑类抗结核新药的药物敏感性进行分析比较,为临床使用提供更多数据支持.方法 收集2021年11月至2023年2月重庆市39个区(县)送至重庆市结核病防治所的培养阳性分离株,采用简单随机抽样的方法,选取经菌种鉴定和比例法药敏试验确定的198株耐多药结核(multi-drug-resistant tuberculosis,MDR-TB)分离株,采用微量肉汤…查看全部>>
This study analysed and compared the drug susceptibility of two nitroimidazoles drugs delamanid(DLM)and pretomanid(PMD)against multidrug-resistant tuberculosis(MDR-TB)isolates in vitro,so as to provide more datas for the clinical application.Culture positive isolates from 39 county TB dispensary were collected and sent to Chongqing Institute for Tuberculosis Control from November 2021 to February 2023.A total of 198 MDR-TB isolates based on simple random sam…查看全部>>
刘文果;朱大冕;冯鑫;沈静;孔珏颖;伏宣霖;胡彦
重庆市结核病防治所,重庆 400050重庆市结核病防治所,重庆 400050重庆市结核病防治所,重庆 400050重庆市结核病防治所,重庆 400050重庆市结核病防治所,重庆 400050重庆市结核病防治所,重庆 400050重庆市结核病防治所,重庆 400050
临床医学
结核分枝杆菌德拉马尼普瑞玛尼药物敏感性耐多药
Mycobacterium tuberculosisdelamanidpretomaniddrug susceptibilityMDR
《中国人兽共患病学报》 2024 (3)
247-252,256,7
重庆市科卫联合医学科研项目(No.2022MSXM102,No.2022-MSXM066)重庆市首批公共卫生重点学科(专科)([2022]72) Supported by Chongqing Medical Scientific Research Project(No.2022MSXM102,No.2022MSXM066)and the First Batch of Key Disciplines On Public Health in Chongqing([2022]72)
评论